Pitt Street Research | Stock research
PSR logo blue.png

TruScreen

TruScreen Group Ltd (NZX: TRU) provides an opto-electrical technology-based real-time, low cost and portable system for the detection of cancer or pre-cancerous cells in cervical tissues. TRU’s disruptive technology is non-invasive for women and provides objective and fast screening, thus providing an efficient alternative to the conventional Pap smear test that requires collection of tissue samples from the cervix.

TruScreen (ASX:TRU)

 

TruScreen Group Ltd (ASX:TRU) provides an opto-electrical technology-based real-time, low cost and portable system for the detection of cancer or pre-cancerous cells in cervical tissues. TRU’s disruptive technology is non-invasive for women and provides objective and fast screening, thus providing an efficient alternative to the conventional Pap smear test that requires collection of tissue samples from the cervix.

14 April 2025

We spoke to Marty Dillon, CEO of Truscreen (ASX:TRU) about the progress TRU has made in getting its TruScreen Cervical Cancer Screening Device to be used in multiple emerging markets. Recent launches of approvals in places as diverse as Vietnam, Indonesia and Uzbekistan bode well for future revenues given the scale of potential screening programmes and the obvious advantages of Truscreen's device.